An “how to” primer for life sciences companies on applying end-to-end evidence strategies in demonstrating product value.
Between now and 2008, $40 billion worth of pharmaceutical industry revenues are at risk through patent expiration on just 19 products in the United States alone. Worldwide, a much more dramatic $72 billion stands to be lost.